Leerink Partnrs Issues Positive Estimate for BEAM Earnings

Beam Therapeutics Inc. (NASDAQ:BEAM) – Research analysts at Leerink Partnrs lifted their Q1 2025 earnings estimates for shares of Beam Therapeutics in a research note issued to investors on Tuesday, March 18th. Leerink Partnrs analyst M. Foroohar now expects that the company will post earnings per share of ($1.20) for the quarter, up from their prior forecast of ($1.26). The consensus estimate for Beam Therapeutics’ current full-year earnings is ($4.57) per share. Leerink Partnrs also issued estimates for Beam Therapeutics’ Q2 2025 earnings at ($1.23) EPS, Q3 2025 earnings at ($1.22) EPS, Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.89) EPS and FY2026 earnings at ($5.08) EPS.

A number of other research analysts also recently commented on the stock. Guggenheim reissued a “buy” rating and set a $78.00 target price on shares of Beam Therapeutics in a research report on Thursday, February 27th. Sanford C. Bernstein raised shares of Beam Therapeutics from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, January 7th. Royal Bank of Canada lifted their price objective on shares of Beam Therapeutics from $24.00 to $26.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 26th. HC Wainwright reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Beam Therapeutics in a research report on Monday, March 10th. Finally, Scotiabank raised shares of Beam Therapeutics from a “sector perform” rating to a “sector outperform” rating and set a $40.00 price objective on the stock in a research report on Monday, March 10th. Two investment analysts have rated the stock with a hold rating, ten have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, Beam Therapeutics has an average rating of “Buy” and an average price target of $50.82.

Beam Therapeutics Stock Performance

NASDAQ BEAM opened at $23.30 on Thursday. The company has a market capitalization of $2.32 billion, a price-to-earnings ratio of -13.24 and a beta of 1.91. The company’s 50-day simple moving average is $26.76 and its two-hundred day simple moving average is $25.91. Beam Therapeutics has a one year low of $20.84 and a one year high of $35.25.

Beam Therapeutics (NASDAQ:BEAM) last posted its earnings results on Tuesday, February 25th. The company reported ($1.09) EPS for the quarter, beating analysts’ consensus estimates of ($1.25) by $0.16. The business had revenue of $30.00 million for the quarter, compared to the consensus estimate of $16.47 million. Beam Therapeutics had a negative net margin of 41.07% and a negative return on equity of 16.22%. The company’s revenue for the quarter was down 90.5% on a year-over-year basis. During the same quarter last year, the firm posted $1.73 EPS.

Insiders Place Their Bets

In other Beam Therapeutics news, insider Christine Bellon sold 1,241 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $24.68, for a total transaction of $30,627.88. Following the completion of the sale, the insider now directly owns 102,968 shares in the company, valued at approximately $2,541,250.24. The trade was a 1.19 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO John M. Evans sold 30,000 shares of Beam Therapeutics stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $26.75, for a total transaction of $802,500.00. Following the sale, the chief executive officer now owns 908,659 shares of the company’s stock, valued at approximately $24,306,628.25. The trade was a 3.20 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 4.20% of the stock is owned by insiders.

Institutional Trading of Beam Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the business. Horizon Kinetics Asset Management LLC lifted its stake in shares of Beam Therapeutics by 4.4% in the 4th quarter. Horizon Kinetics Asset Management LLC now owns 9,597 shares of the company’s stock valued at $238,000 after purchasing an additional 403 shares during the period. Summit Investment Advisors Inc. lifted its stake in shares of Beam Therapeutics by 6.6% in the 4th quarter. Summit Investment Advisors Inc. now owns 7,999 shares of the company’s stock valued at $198,000 after purchasing an additional 496 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Beam Therapeutics by 2.5% in the 3rd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 21,396 shares of the company’s stock valued at $524,000 after purchasing an additional 516 shares during the period. Martingale Asset Management L P lifted its stake in shares of Beam Therapeutics by 8.6% in the 4th quarter. Martingale Asset Management L P now owns 11,438 shares of the company’s stock valued at $284,000 after purchasing an additional 909 shares during the period. Finally, Swiss National Bank lifted its stake in shares of Beam Therapeutics by 0.8% in the 4th quarter. Swiss National Bank now owns 137,800 shares of the company’s stock valued at $3,417,000 after purchasing an additional 1,100 shares during the period. 99.68% of the stock is currently owned by institutional investors and hedge funds.

About Beam Therapeutics

Beam Therapeutics Inc, a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.